CY1109506T1 - ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ - Google Patents

ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ

Info

Publication number
CY1109506T1
CY1109506T1 CY20091100970T CY091100970T CY1109506T1 CY 1109506 T1 CY1109506 T1 CY 1109506T1 CY 20091100970 T CY20091100970 T CY 20091100970T CY 091100970 T CY091100970 T CY 091100970T CY 1109506 T1 CY1109506 T1 CY 1109506T1
Authority
CY
Cyprus
Prior art keywords
approved
measles virus
vaccine strain
immune
synthesis
Prior art date
Application number
CY20091100970T
Other languages
English (en)
Inventor
Frédéric Tangy
Chantal Combredet
Valérie Labrousse-Najburg
Michel Brahic
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109506(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1109506T1 publication Critical patent/CY1109506T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/12—Mumps virus; Measles virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η εφεύρεση σχετίζεται με ένα μόριο cDNA του οποίου εγκωδικεύει την αλληλουχία νουκλεοτιδίων του αντιγονιδιωματικού κλώνου (+)RNA πλήρους μήκους ενός ιού ιλαράς (MV) που προέρχεται από ένα εγκεκριμένο στέλεχος εμβολίου. Αφορά επίσης την παρασκευή ανοσογόνων συνθέσεων χρησιμοποιώντας το εν λόγω cDNA.
CY20091100970T 2002-06-20 2009-09-18 ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ CY1109506T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02291551A EP1375512B1 (en) 2002-06-20 2002-06-20 Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions

Publications (1)

Publication Number Publication Date
CY1109506T1 true CY1109506T1 (el) 2014-08-13

Family

ID=29716946

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100970T CY1109506T1 (el) 2002-06-20 2009-09-18 ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ

Country Status (15)

Country Link
US (3) US9005961B2 (el)
EP (5) EP2110382A1 (el)
KR (1) KR101227128B1 (el)
CN (1) CN100577683C (el)
AT (1) ATE437175T1 (el)
AU (1) AU2003266950A1 (el)
BR (1) BRPI0312173B8 (el)
CA (1) CA2489052C (el)
CY (1) CY1109506T1 (el)
DE (1) DE60233038D1 (el)
DK (2) DK1375512T3 (el)
ES (2) ES2330309T3 (el)
HK (1) HK1061568A1 (el)
PT (1) PT1375512E (el)
WO (1) WO2004000876A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
ATE437175T1 (de) 2002-06-20 2009-08-15 Pasteur Institut Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2009005917A2 (en) * 2007-05-29 2009-01-08 Vical Incorporated Methods of treating measles infectious disease in mammals
JP5619614B2 (ja) * 2007-11-26 2014-11-05 ロンドン スクール オブ ハイジーン アンド トロピカル メディシンＬｏｎｄｏｎ Ｓｃｈｏｏｌ Ｏｆ Ｈｙｇｉｅｎｅ ＆ Ｔｒｏｐｉｃａｌ Ｍｅｄｉｃｉｎｅ レオウイルス科のウイルスのワクチン用ウイルス株を製造する方法
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP2959915A1 (en) 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3103474A1 (en) 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
JP6949468B2 (ja) * 2016-10-17 2021-10-13 ルプレヒト−カールス−ウニベルジテート ハイデルベルク 腫瘍抗原をコードする麻疹ウイルス
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CA3085224A1 (en) * 2017-12-21 2019-06-27 Institut Pasteur Measles-vectored lassa vaccine
CN111218475A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救麻疹Schwarz/Moraten疫苗株的系统和方法
EP4103282A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Measles-vectored covid-19 immunogenic compositions and vaccines
EP3865180A1 (en) * 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
EP3936517A1 (en) 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
EP4310186A1 (en) * 2021-03-15 2024-01-24 Misako Yoneda Recombinant measles virus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) * 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
CZ300172B6 (cs) 1997-02-28 2009-03-04 Acambis Inc. Chimerický živý, infekcní, oslabený virus, lécivopro prevenci nebo lécbu flavivirových infekcí s jeho obsahem a molekula nukleové kyseliny jej kódující
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
EP1064358A2 (en) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
JP4625915B2 (ja) * 1998-06-03 2011-02-02 ワイス・ホールディングズ・コーポレイション Ｒｎａウイルスの新規レスキュー方法
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
MXPA02001177A (es) 1999-08-02 2002-07-02 Wyeth Corp Recuperacion del virus de las paperas del acido desoxirribonucleico recombinante.
BRPI0110607B8 (pt) * 2000-04-28 2021-05-25 St Jude Childrens Res Hospital sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado
ES2427139T3 (es) * 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
ATE437175T1 (de) * 2002-06-20 2009-08-15 Pasteur Institut Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EA027784B1 (ru) * 2008-05-26 2017-09-29 Кадила Хелзкэр Лимитед Комбинированная вакцина против кори и вируса папилломы человека
MY175250A (en) * 2009-05-05 2020-06-17 Cadila Healthcare Ltd Combined measles-malaria vaccine

Also Published As

Publication number Publication date
KR20050058288A (ko) 2005-06-16
US9005925B2 (en) 2015-04-14
EP2311853B1 (en) 2017-12-27
EP2065393A1 (en) 2009-06-03
DE60233038D1 (de) 2009-09-03
US9005961B2 (en) 2015-04-14
ATE437175T1 (de) 2009-08-15
EP2311853A1 (en) 2011-04-20
AU2003266950A1 (en) 2004-01-06
CA2489052A1 (en) 2003-12-31
US9701944B2 (en) 2017-07-11
US20050227224A1 (en) 2005-10-13
EP2110382A1 (en) 2009-10-21
ES2663224T3 (es) 2018-04-11
CA2489052C (en) 2014-07-29
DK2311853T3 (en) 2018-04-16
HK1061568A1 (en) 2004-09-24
WO2004000876A1 (en) 2003-12-31
EP1375512A1 (en) 2004-01-02
BR0312173A (pt) 2005-04-05
BRPI0312173B8 (pt) 2021-05-25
EP1513872A1 (en) 2005-03-16
PT1375512E (pt) 2009-09-23
US20130296541A1 (en) 2013-11-07
EP1375512B1 (en) 2009-07-22
CN1662553A (zh) 2005-08-31
BRPI0312173B1 (pt) 2019-05-07
AU2003266950A8 (en) 2004-01-06
CN100577683C (zh) 2010-01-06
KR101227128B1 (ko) 2013-01-29
DK1375512T3 (da) 2009-10-26
WO2004000876A8 (en) 2005-03-03
US20150275184A1 (en) 2015-10-01
ES2330309T3 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
CY1109506T1 (el) ΛΟΙΜΟΓΟΝΟ cDNA ΕΝΟΣ ΕΓΚΕΚΡΙΜΕΝΟΥ ΣΤΕΛΕΧΟΥΣ ΕΜΒΟΛΙΟΥ ΤΟΥ ΙΟΥ ΤΗΣ ΙΛΑΡΑΣ. ΧΡΗΣΗ ΓΙΑ ΑΝΟΣΟΓΟΝΕΣ ΣΥΝΘΕΣΕΙΣ
CY1118372T1 (el) Νεα μεθοδος και συνθεσεις
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
DE60335350D1 (de) Adjuvantien für dns impstoffe basierend auf imidazochinoline
CY1112749T1 (el) Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
MA30581B1 (fr) Vaccin viral recombinant
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
CY1112634T1 (el) Εμβολια κατα της ελονοσιας που βασιζονται σε ανασυνδυασμενο ιο
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CY1115253T1 (el) Κρυσταλλικες μορφες ενος παραγωγου 2-θειαζολυλο-4-κινολινυλ-οξυ-ομαδας, ενος ισχυρου αναστολεα του ηcv
CY1111709T1 (el) Προϊοντα συζευξης φωσφονικου νουκλεοσιδιου ως αντι hiv παραγοντες
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE426412T1 (de) Adjuvante influenza-vakzine
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
CY1110630T1 (el) Οικογενεια γονιδιων παρομοιων με τα msp-3
FR2829498B1 (fr) Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
CY1107845T1 (el) Γενετικα εμβολια με ανοσοενισχυτικο
BR0316722A (pt) Constructos genéticos e composições compreendendo rre e cte e usos destes
CY1118060T1 (el) Εμβολιο δεικτης για κλασικη πανωλη των χοιρων
BR9713540A (pt) Procedimento para a expressão do gene do vìrus da dengue
CY1113749T1 (el) Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους